Cargando…
Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy
BACKGROUND: An experienced life-threating anaphylactic reaction to hymenoptera venom can sustainably impair patients’ quality of life (QoL). Besides carrying emergency medication, venom-specific immunotherapy (VIT) exists as a causal treatment of allergy. OBJECTIVE: This study aimed to examine QoL,...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085710/ https://www.ncbi.nlm.nih.gov/pubmed/33995819 http://dx.doi.org/10.1016/j.waojou.2021.100536 |
_version_ | 1783686401720582144 |
---|---|
author | Eitel, Tamara Zeiner, Kim Nikola Assmus, Katharina Ackermann, Hanns Zoeller, Nadja Meissner, Markus Kaufmann, Roland Kippenberger, Stefan Valesky, Eva Maria |
author_facet | Eitel, Tamara Zeiner, Kim Nikola Assmus, Katharina Ackermann, Hanns Zoeller, Nadja Meissner, Markus Kaufmann, Roland Kippenberger, Stefan Valesky, Eva Maria |
author_sort | Eitel, Tamara |
collection | PubMed |
description | BACKGROUND: An experienced life-threating anaphylactic reaction to hymenoptera venom can sustainably impair patients’ quality of life (QoL). Besides carrying emergency medication, venom-specific immunotherapy (VIT) exists as a causal treatment of allergy. OBJECTIVE: This study aimed to examine QoL, anxiety, depression, and physical and mental health in patients allergic to hymenoptera venom before and during VIT and the impact of a tolerated sting challenge (SC). METHODS: Between July 2017 and August 2017, 142 patients with venom allergy were analyzed using validated questionnaires as the: Vespid Allergy Quality for Life Questionnaire" (VQLQ-d), the "Hospital Anxiety and Depression Scale" (HADS-D) and the "Short Form 36" (SF-36). To evaluate the impact of VIT and SC on the QoL, patients were divided into 3 groups: (A) VIT and tolerated SC (n = 45), (B) VIT before carrying out SC (n = 73), and (C) therapy-naïve before VIT (n = 20). Further parameters like gender, age, insect species, and severity of the anaphylactic reaction were assessed. RESULTS: A significant correlation between the health-related QoL and the parameters of gender and state of treatment was seen. Especially male patients, as well as patients allergic to yellow jacket venom, benefit from a SC in terms of a significant increase in their QoL. In the total study cohort, a clear trend was observed towards a higher QoL in patients under VIT who tolerated a SC. Overall, neither the patients’ age nor the insect species exerted a relevant influence on QoL, depression or anxiety. However, women showed a lower QoL combined with higher anxiety and depression scores than men. CONCLUSION: Immunotherapy leads to an improved QoL, which can be further increased by a SC. A tolerated SC conceivably reassures the patients by objectifying the treatment success. Female patients appear to have a stronger impaired QoL per se. Taken together, a SC can be performed during VIT to strengthen the patients’ QoL. |
format | Online Article Text |
id | pubmed-8085710 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | World Allergy Organization |
record_format | MEDLINE/PubMed |
spelling | pubmed-80857102021-05-13 Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy Eitel, Tamara Zeiner, Kim Nikola Assmus, Katharina Ackermann, Hanns Zoeller, Nadja Meissner, Markus Kaufmann, Roland Kippenberger, Stefan Valesky, Eva Maria World Allergy Organ J Article BACKGROUND: An experienced life-threating anaphylactic reaction to hymenoptera venom can sustainably impair patients’ quality of life (QoL). Besides carrying emergency medication, venom-specific immunotherapy (VIT) exists as a causal treatment of allergy. OBJECTIVE: This study aimed to examine QoL, anxiety, depression, and physical and mental health in patients allergic to hymenoptera venom before and during VIT and the impact of a tolerated sting challenge (SC). METHODS: Between July 2017 and August 2017, 142 patients with venom allergy were analyzed using validated questionnaires as the: Vespid Allergy Quality for Life Questionnaire" (VQLQ-d), the "Hospital Anxiety and Depression Scale" (HADS-D) and the "Short Form 36" (SF-36). To evaluate the impact of VIT and SC on the QoL, patients were divided into 3 groups: (A) VIT and tolerated SC (n = 45), (B) VIT before carrying out SC (n = 73), and (C) therapy-naïve before VIT (n = 20). Further parameters like gender, age, insect species, and severity of the anaphylactic reaction were assessed. RESULTS: A significant correlation between the health-related QoL and the parameters of gender and state of treatment was seen. Especially male patients, as well as patients allergic to yellow jacket venom, benefit from a SC in terms of a significant increase in their QoL. In the total study cohort, a clear trend was observed towards a higher QoL in patients under VIT who tolerated a SC. Overall, neither the patients’ age nor the insect species exerted a relevant influence on QoL, depression or anxiety. However, women showed a lower QoL combined with higher anxiety and depression scores than men. CONCLUSION: Immunotherapy leads to an improved QoL, which can be further increased by a SC. A tolerated SC conceivably reassures the patients by objectifying the treatment success. Female patients appear to have a stronger impaired QoL per se. Taken together, a SC can be performed during VIT to strengthen the patients’ QoL. World Allergy Organization 2021-04-21 /pmc/articles/PMC8085710/ /pubmed/33995819 http://dx.doi.org/10.1016/j.waojou.2021.100536 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Eitel, Tamara Zeiner, Kim Nikola Assmus, Katharina Ackermann, Hanns Zoeller, Nadja Meissner, Markus Kaufmann, Roland Kippenberger, Stefan Valesky, Eva Maria Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy |
title | Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy |
title_full | Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy |
title_fullStr | Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy |
title_full_unstemmed | Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy |
title_short | Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy |
title_sort | impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085710/ https://www.ncbi.nlm.nih.gov/pubmed/33995819 http://dx.doi.org/10.1016/j.waojou.2021.100536 |
work_keys_str_mv | AT eiteltamara impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy AT zeinerkimnikola impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy AT assmuskatharina impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy AT ackermannhanns impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy AT zoellernadja impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy AT meissnermarkus impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy AT kaufmannroland impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy AT kippenbergerstefan impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy AT valeskyevamaria impactofspecificimmunotherapyandstingchallengeonthequalityoflifeinpatientswithhymenopteravenomallergy |